Images List Premium Download Classic

Leukemia

Leukemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Therapeutic method and medicament for htlv-1 associated myelopathy
Kyowa Hakko Kirin Co., Ltd
July 20, 2017 - N°20170204189

The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human t cell leukemia virus type-1 (also known as human t lymphotropic virus type-1) associated myelopathy (ham) patients and asymptomatic htlv-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent ...
Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity
Bioniz, Llc
July 20, 2017 - N°20170204153

The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. ...
Combination of lenalidomide and polypeptide construct, and uses thereof
Teva Pharmaceuticals Australia Pty Ltd
July 20, 2017 - N°20170202962

Methods for cancer treatment include administering to a cancer patient an anti-cd38 antibody-attenuated human ifn alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise cd-38 expressing tumor cells, including b-cell lymphoma, multiple myeloma, non-hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cobalt porphyrins for the treatment of blood-related disorders
Uniwersytet Jagiellonski
July 13, 2017 - N°20170196882

The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem ...
Methods for manipulating phagocytosis mediated by cd47
The Board Of Trustees Of The Leland Stanford Junior University
July 06, 2017 - N°20170190776

Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e. G. Circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating ...
Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
The Board Of Trustees Of The Leland Stanford Junior University
July 06, 2017 - N°20170190700

Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the n2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Diagnostic of chronic myelomonocytic leukemia (cmml) by flow cytometry
Institut Gustave-roussy
June 29, 2017 - N°20170184598

The present invention relates to an in vitro method of diagnosing chronic myelomonocytic leukemia (cmml) in a subject, said method comprising the steps of: a) detecting a monocyte population in a biological sample from said subject; b) quantifying the cd14+/cd16− monocytes in said biological sample; c) comparing the value of step b) to a reference value; and d) ...
Treating chronic myelogenous leukemia (cml)
University Of Massachusetts
June 29, 2017 - N°20170183741

Methods for treating chronic myeloid leukemia (cml), e. G., bcr-abl inhibitor imatinib mesylate (im)-resistant cml, using combination treatments, e. G., combined treatment with a bcr-abl inhibitor, e. G., im, and a mek inhibitor, e. G., trametinib.
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
June 29, 2017 - N°20170183418

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a bcma monoclonal antibody, conferring specific immunity against bcma positive cells. The engineered immune cells endowed with such cars are particularly ...
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
The Trustees Of The University Of Pennsylvania
June 29, 2017 - N°20170183415

The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (aml) and b-cell acute lymphoid leukemia (b-all). The invention also relates to at least one chimeric antigen receptor (car) specific to cd123, vectors comprising the same, and recombinant t cells comprising the cd123 car. The invention also includes methods of administering a genetically modified t cell ...
Cd123 specific chimeric antigen receptors for cancer immunotherapy
Cellectis
June 29, 2017 - N°20170183413

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a cd123 monoclonal antibody, conferring specific immunity against cd123 positive cells. The engineered immune cells endowed with such cars are particularly ...
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 29, 2017 - N°20170183355

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and ...
Composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer
Syros Pharmaceuticals, Inc.
June 22, 2017 - N°20170175118

This invention generally relates to a composition and method of using mam-made small rnas, such as small interfering rnas (sirna), micrornas (mirna) and their hairpin-like precursors (pre-mirna), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination of anti-pd-1 antibodies and anti-cd20/anti-cd3 antibodies to treat cancer
Regeneron Pharmaceuticals, Inc.
June 22, 2017 - N°20170174779

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e. G., a b-cell cancer such as hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (...
Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
Temple University-of The Commonwealth System Of Higher Education
June 22, 2017 - N°20170174734

The present invention provides compositions and methods of treating cancer by inducing the cellular differentiation activity of angiocidin.
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 22, 2017 - N°20170174692

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, ...
Substituted indole mcl-1 inhibitors
Vanderbilt University
June 22, 2017 - N°20170174689

The present invention provides for compounds that inhibit the activity of an anti-apoptotic bcl-2 family member myeloid cell leukemia-1 (mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e. G., cancer) characterized by the over-expression or dysregulation of mcl-1 protein.
Pyrazolone compounds and uses thereof
Inception 2, Inc.
June 22, 2017 - N°20170174666

The invention disclosed herein is directed to compounds of formula i [formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of formula ...
Combination therapy with volasertib
Boehringer Ingelheim International Gmbh
June 22, 2017 - N°20170173023

Disclosed is the use of volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising administering a high dose of volasertib in combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (gcsf) or in combination with fludarabine, cytarabine, gcsf and a daunorubicin citrate liposome injection.
Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
St. Jude Children's Research Hospital
June 22, 2017 - N°20170173021

A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of myc in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of myc indicates a sensitivity to a treatment by a cdk9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and ...
Histone deacetylase (hdac) inhibitors for the treatment of cancer
Topotarget Uk Limited
June 22, 2017 - N°20170172997

The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e. G., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (hdac) inhibitor as described herein, for example, ...
Loading